John L. Higgins is CEO at LIGAND PHARMACEUTICALS INC (LGND). They have made 52 open-market trades across 3 companies since 2007, most recently 2026-09-28.
CIK 0001208906
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
15 open-market purchases totalling $2.1M since 2007, against 37 sales. Across 15 scored buys the stock is down 3.6% at ninety days, and 6.1 points behind the S&P over the same stretch.
15 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| LGND | 417,695 | $123.4M |
| OABI | 2,962,320 | $13.6M |
| TECH | 77,254 | $5.6M |
| CNCT | 72,984 | — |
| LGNDD | 107,275 | — |
| Total | $142.6M |
Shares reported on the most recent Form 4, priced at the 2026-09-30 close. 2 holdings could not be priced and are excluded from the total.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 27% | 33% | 20% |
| Avg Move | -5.0% | -0.8% | -3.6% |
| Alpha | -1.9% | -0.8% | -6.1% |
| Scored | 15 | 15 | 15 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OABI | BUY | 2025-11-06 | 2025-11-10 | $1.39 | $215K | +11.3% | +33.3% | +19.3% |
| OABI | BUY | 2025-05-12 | 2025-05-13 | $1.44 | $94K | -3.5% | +19.6% | +37.1% |
| OABI | BUY | 2025-03-21 | 2025-03-21 | $2.28 | $9K | -10.3% | -28.8% | -38.1% |
| OABI | BUY | 2025-03-20 | 2025-03-20 | $2.35 | $591K | -2.6% | -21.8% | -29.5% |
| TECH | SELL | 2024-05-14 | 2024-05-16 | $83.84 | $335K | -5.3% | -9.8% | -12.3% |
| OABI | SELL | 2023-05-23 | 2023-05-25 | $4.05 | $36K | +8.6% | +11.3% | +37.4% |
| OABI | SELL | 2023-05-19 | 2023-05-23 | $4.05 | $4K | +3.5% | +13.1% | +35.2% |
| OABI | SELL | 2023-05-18 | 2023-05-19 | $3.89 | $195K | +9.0% | +25.0% | +50.8% |
| LGND | SELL | 2022-12-16 | 2022-12-20 | $61.87 | $619K | +4.0% | +11.6% | +12.9% |
| LGND | SELL | 2022-11-17 | 2022-11-21 | $78.32 | $1.6M | -7.2% | -16.6% | -9.5% |
| LGND | SELL | 2022-09-16 | 2022-09-22 | $88.06 | $88K | +16.5% | +7.7% | -19.0% |
| LGND | SELL | 2022-09-15 | 2022-09-16 | $90.00 | $180K | -2.7% | +7.8% | -29.0% |
| TECH | SELL | 2022-08-10 | 2022-08-12 | $379.97 | $1.5M | -8.7% | -9.3% | -11.3% |
| TECH | SELL | 2022-06-07 | 2022-06-09 | $365.28 | $804K | -5.7% | +3.8% | -4.4% |
| LGND | SELL | 2021-11-12 | 2021-11-12 | $160.50 | $482K | +0.4% | -11.0% | -25.7% |
| LGND | SELL | 2021-02-05 | 2021-02-09 | $203.40 | $22.2M | -36.1% | -28.4% | -42.2% |
| LGND | SELL | 2021-01-25 | 2021-01-27 | $169.22 | $15.2M | +34.3% | -4.4% | -2.5% |
| TECH | SELL | 2020-11-06 | 2020-11-10 | $300.35 | $1.5M | +0.6% | +0.7% | +28.9% |
| TECH | SELL | 2020-02-12 | 2020-02-14 | $205.23 | $1.0M | -7.6% | -22.8% | +25.5% |
| LGND | BUY | 2019-07-31 | 2019-07-31 | $95.45 | $353K | -2.6% | -2.6% | +20.5% |
| TECH | SELL | 2019-06-04 | 2019-06-06 | $203.67 | $2.0M | -0.7% | +1.6% | -10.5% |
| LGND | BUY | 2019-05-31 | 2019-05-31 | $108.20 | $108K | +1.4% | +5.5% | -15.8% |
| LGND | BUY | 2019-05-14 | 2019-05-14 | $113.50 | $284K | +0.6% | +1.0% | -19.3% |
| LGND | BUY | 2019-03-13 | 2019-03-15 | $114.29 | $286K | +0.7% | +4.8% | -5.2% |
| LGND | SELL | 2018-08-30 | 2018-08-31 | $258.25 | $904K | -1.8% | +4.5% | -36.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.